NCT06943521 2025-12-11A Study of MT-4561 in Patients With Various Advanced Solid TumorsTanabe Pharma America, Inc.Phase 1/2 Recruiting27 enrolled
NCT03093116 2025-07-10TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 2 FDA
NCT00781911 2019-09-20A Study of Cixutumumab (IMC-A12) in Islet Cell CancerEli Lilly and CompanyPhase 2 Completed43 enrolled 12 charts
NCT01525550 2019-07-30A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine TumorsPfizerPhase 4 Completed106 enrolled 26 charts
NCT00050349 2017-03-01EPO906 in Carcinoid and Other Neuroendocrine TumorsNovartisPhase 2 Completed33 enrolled
NCT00363051 2013-05-10Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to ChemotherapyNovartisPhase 2 Completed160 enrolled 17 charts